Can vaccines be delivered via the lungs instead of by injection?

In addition to the obvious benefit of eliminating the need for an injection, new vaccine delivery methods via the lungs offer particular advantages for protecting against infectious agents that enter the body through the respiratory track. A comprehensive review article that presents the current status, challenges, and opportunities of pulmonary vaccine delivery is published in Journal of Aerosol Medicine and Pulmonary Drug Delivery.

In "Pulmonary Vaccine Delivery: A Realistic Approach?" Wouter Tonnis and coauthors from University of Groningen and National Institute for Public Health and the Environment (Bilthoven), The Netherlands, describe the unique physiology and immune responsiveness of the respiratory track that make pulmonary vaccine delivery such an attractive alternative to traditional injections. Although pulmonary vaccination is still a young field, with much more research needed, evidence suggests administration of a vaccine to the lungs can induce a local more effectively than conventional types of vaccine delivery, in addition to stimulating throughout the body. This could be especially important for combating pathogens that cause pulmonary diseases.

"The lung is an immunologic powerhouse that remains largely unexplored. Theoretically we should be able to avoid needles and simply inhale our vaccines," says Editor-in-Chief Gerald C. Smaldone, MD, PhD, Professor and Chief, Division of Pulmonary and at SUNY-Stony Brook.

More information: The article is available free online on the Journal of Aerosol Medicine and Pulmonary Drug Delivery website.

add to favorites email to friend print save as pdf

Related Stories

Tattooing improves response to DNA vaccine

Feb 07, 2008

A tattoo can be more than just a fashion statement – it has potential medical value, according to an article published in the online open access journal, Genetic Vaccines and Therapy.

Nasal spray vaccines more effective against flu

Apr 12, 2011

Nasal vaccines that effectively protect against flu, pneumonia and even bioterrorism agents such as Yersinia pestis that causes the plague, could soon be a possibility, according to research presented at the Society for General ...

New development could increase flu vaccine supply

Jun 02, 2011

(Medical Xpress) -- Scientists from the U.S. Food and Drug Administration and the pharmaceutical company Novartis announced today in the journal Science Translational Medicine that they have developed a new adjuvant, or com ...

Recommended for you

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments